American Association for Cancer Research

Skip to Main Content

Table 3.

Plasma GST-α concentration before and after 4 wks of daily Polyphenon E administration

	GST-α concentration (ng/mL)*			P
		Baseline	Posttreatment	P
All participants (N = 42)	7.46 ± 6.54	7.59 ± 6.91	0.770
Baseline level in the lowest tertile (n = 14)	3.32 ± 0.54	5.17 ± 4.19	0.136
Baseline level in the middle tertile (n = 14)	5.52 ± 0.66	5.09 ± 1.65	0.334
Baseline level in the highest tertile (n = 14)	13.5 ± 8.47	12.5 ± 9.53	0.003

	GST-α concentration (ng/mL)*			P
		Baseline	Posttreatment	P
All participants (N = 42)	7.46 ± 6.54	7.59 ± 6.91	0.770
Baseline level in the lowest tertile (n = 14)	3.32 ± 0.54	5.17 ± 4.19	0.136
Baseline level in the middle tertile (n = 14)	5.52 ± 0.66	5.09 ± 1.65	0.334
Baseline level in the highest tertile (n = 14)	13.5 ± 8.47	12.5 ± 9.53	0.003

Mean ± 1 SD.